MedTrace Logo

To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307

NCT05783570 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-03-15

No results posted yet for this study

Summary

To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 (GPC3) Targeted Chimeric Antigen Receptor T cell therapy in Patients with GPC3 Positive Advanced Hepatocellular Carcinoma who Have Failed Standard Therapy

Conditions

Interventions

BIOLOGICAL

EU307 CAR-T Cell

* Dose to be administered: a single dose * IV administration * Dosing rate: To be administrated at a rate of approximately 2 mL/min

Sponsors & Collaborators

  • Eutilex

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-24
Primary Completion
2025-06-30
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05783570 on ClinicalTrials.gov